Company news

IceCure Medical Ltd. news in 2026

IceCure Medical Ltd.'s news releases, calls and decks from 2026, newest first.

View company

IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation

October 27, 2026

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

October 20, 2026

IceCure Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026

October 13, 2026

IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site

October 6, 2026

IceCure Medical Receives Regulatory Approval to Market ProSense® in China

September 10, 2026

IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands

August 24, 2026

West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation

August 20, 2026

Initial Statement of Beneficial Ownership (Form 3)

August 17, 2026

IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation

August 13, 2026

IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year

August 12, 2026

IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment

August 6, 2026

IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026

August 5, 2026

IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®

July 29, 2026

IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site

July 27, 2026

IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation

July 14, 2026

Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer

July 6, 2026

IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

June 25, 2026

IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer

June 23, 2026

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

June 17, 2026

IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance

June 17, 2026

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

June 1, 2026

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

May 18, 2026

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

May 13, 2026

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

May 12, 2026

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

May 6, 2026

IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

May 5, 2026

IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

April 21, 2026

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

March 25, 2026

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

March 24, 2026

IceCure Appoints Meir Peleg as Chief Financial Officer

March 23, 2026

IceCure Reports 2025 Full Year Financial & Operational Results

March 17, 2026

U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

March 10, 2026

IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

March 10, 2026

American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer

March 9, 2026

IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas

March 2, 2026

IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026

February 23, 2026

IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation

February 19, 2026

IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®

February 11, 2026

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

February 9, 2026

IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

January 28, 2026

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

January 12, 2026

Calls in 2026

Decks in 2026